Recent Publications
1. Nath K, Nelson DS, Roman J, Putt ME, Lee SC, Leeper DB & Glickson JD. Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide. Anticancer Res. 2017;37(7):3413-21.
2. Nancolas B, Guo L, Zhou R, Nath K, Nelson DS, Leeper DB, Blair IA, Glickson JD & Halestrap AP. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016. PMCID: PMC4814305.
3. Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, Roman J, Zhou R, Leeper DB, Halestrap AP. Blair IA & Glickson JD. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866(2):151-62. PMCID: PMC5138080.
4. Xu HN, Feng M, Nath K, Nelson D, Roman J, Zhao H, Lin Z, Glickson J & Li LZ. Optical Redox Imaging of Lonidamine Treatment Response of Melanoma Cells and Xenografts. Mol Imaging Biol. 2019;21(3):426-35. doi: 10.1007/s11307-018-1258-z.
5. Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, Wang HY, Pickup S, Nath K, Lu P, Hofbauer S, Mesaros C, Wang YL, Nelson DS, Schuster SJ, Blair IA, Glickson JD & Wasik MA. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells. Mol Cancer Res. 2019;17(6):1365-77. doi: 10.158/541-7786.MCR-18-0256. Epub 2019 Mar 12.
Contact Us
Phone: 215-898-1805
Fax: 215-573-2113